Compare ZYME & AVAH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZYME | AVAH |
|---|---|---|
| Founded | 2003 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hospital/Nursing Management |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2022 | 2021 |
| Metric | ZYME | AVAH |
|---|---|---|
| Price | $22.49 | $7.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 9 |
| Target Price | ★ $38.90 | $9.75 |
| AVG Volume (30 Days) | 608.4K | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 33.33 | ★ 1850.00 |
| EPS | N/A | ★ 0.19 |
| Revenue | $105,965,000.00 | ★ $2,433,199,000.00 |
| Revenue This Year | $183.10 | $7.31 |
| Revenue Next Year | N/A | $5.59 |
| P/E Ratio | ★ N/A | $38.05 |
| Revenue Growth | ★ 38.87 | 20.19 |
| 52 Week Low | $11.86 | $3.73 |
| 52 Week High | $29.75 | $10.32 |
| Indicator | ZYME | AVAH |
|---|---|---|
| Relative Strength Index (RSI) | 34.96 | 62.36 |
| Support Level | $22.28 | $6.22 |
| Resistance Level | $23.66 | $7.52 |
| Average True Range (ATR) | 0.89 | 0.38 |
| MACD | -0.14 | 0.04 |
| Stochastic Oscillator | 8.05 | 95.45 |
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Aveanna Healthcare Holdings Inc is a diversified home care platform that provides care to medically complex, high-cost patient populations. It directly addresses the pressing challenges facing the U.S. healthcare system by providing safe, high-quality care in the home. The firm provides its services through three segments: Private Duty Services (PDS); Home Health & Hospice (HHH); and Medical Solutions (MS). The Private Duty Services segment generates the majority of revenue, which includes private duty skilled nursing services, non-clinical and personal care services, and pediatric therapy services, and is principally reimbursed by Medicaid and Medicaid MCO.